CU-06 is under clinical development by Thea Open Innovation SASU and currently in Phase I for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to GlobalData, Phase I drugs for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CU-06’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CU-06 overview

CU-06 is under development for the treatment of diabetic macular edema, wet  macular degeneration, stroke, myocardial infarction, ulcerative colitis, and hereditary angioedema, colon cancer. It is administered through oral route. The drug candidate acts by targeting NF-κB inflammatory signaling pathway.

It was also under development for the treatment of diabetic retinopathy, acute respiratory distress syndrome, unstable angina, ulcerative colitis, and Crohn's disease.

Thea Open Innovation SASU overview

Thea Open Innovation SASU is a biotechnology company that aim is to identify, evaluate and support the most innovative developments in eye care, throughout licensing agreements and/or equity investments. The company is headquartered in Clermont Ferrand, A

For a complete picture of CU-06’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.